Basilea Pharmaceutica Ltd. Logo


Tuesday, September 13. 2016
Basel, Switzerland, September 13, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply, distribution and license agreement with Grupo Biotoscana S.L., (GBT) for Basilea's antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in 19 countries in Latin America including Brazil, Mexico, Argentina and Colombia.
Tuesday, September 06. 2016
Basel, Switzerland, September 6, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient has been dosed in a new phase 1/2a continuous infusion study with its tumor checkpoint controller BAL101553 in patients with advanced solid cancers. Continuous infusion with portable pumps is an established mode of drug administration used for the treatment of certain cancers.
Wednesday, August 17. 2016
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
Monday, August 15. 2016
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
Monday, June 27. 2016
Basel, Switzerland, June 27, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its new azole antifungal CRESEMBA® (isavuconazole) in Italy and will sponsor today a continuing medical education event on current challenges and recent developments in the management of invasive fungal infections in Bologna, Italy. The event will be co-chaired by Prof. Claudio Viscoli MD, Professor of Infectious Diseases, University of Genova and Prof. Corrado Girmenia MD, Professor of Haematology, Sapienza University of Rome.
Thursday, June 09. 2016
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
Thursday, April 21. 2016
Basel, Switzerland, April 21, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that the shareholders approved all agenda items proposed by the Board of Directors at today's Ordinary General Meeting of Shareholders (AGM) for the financial year 2015. At the meeting, 33.2 percent of Basilea's share capital was represented.
Thursday, April 21. 2016
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
Wednesday, April 20. 2016
Basel, Switzerland, April 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International Ltd. ("Basilea") for the clinical phase 3 development aiming at regulatory approval of Basilea's broad-spectrum antibiotic ceftobiprole in the United States.
Friday, April 15. 2016
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
more back